Legend Biotech Announces Presentations at ASCO 2026
Legend Biotech will present preliminary Phase 1 data for LB2102, its DLL3-targeted CAR-T therapy for solid tumors, in a rapid oral presentation at ASCO 2026. The data highlights early evidence of clinical activity in small-cell lung cancer and large-cell neuroendocrine carcinoma, alongside a manageable safety profile.
Key figures
- Drug Name
- LB2102
- Phase Of Trial
- Phase 1
- Patients treated carvykti
- 10,000+
- Countries carvykti available
- 18
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.